Cannabis treatment in hospitalized patients using the SYQE inhaler: Results of a pilot open-label study. Issue 1 (February 2020)

• Record Type: Journal Article
• Authors: Vulfsons, Simon; Ognitz, Miriam; Bar-Sela, Gil; Raz-Pasteur, Ayelet; Eisenberg, Elon
• Is Part Of: Palliative & supportive care. Volume 18:Issue 1(2020)
• Page Start: 12
• Page End: 17
• Publication Date: 2020-02
• Subjects: Syqe inhaler, -- medical cannabis, -- hospital setting, -- pain, -- spasticity, -- CINV, -- user/nurse satisfaction; Palliative treatment -- Great Britain -- Periodicals; 616.029
• DOI: 10.1017/S147895151900021X
• Languages: English
• ISSNs: 1478-9515

Abstract

Abstract: Objective: The objectives were to evaluate the, usability, feasibility of use, satisfaction, and safety of the Syqe Inhaler Exo (Syqe Inhaler), a metered dose, Pharmacokinetics-validated, cannabis inhaler device in a cohort of hospitalized patients that were using medical cannabis under license as a part of their ongoing medical treatment. Method: Before and after inhaling from the Syqe Inhaler, participants were asked to fill a questionnaire regarding pain reduction on a visual analog scale from 0 to 10 and, if relevant, reduction in chemotherapy-induced nausea and vomiting and/or spasticity. A patient satisfaction questionnaire and a usability questionnaire were filled in following the last use. Prescribed treatment included 4 daily doses of 500 μg tetrahydrocannabinol each delivered from 16 mg cannabis flos per inhalation plus up to an additional four SOS (distress code for more doses of cannabis) doses. Result: Daily cannabis dose consumed during hospitalization with the Syqe Inhaler was 51 mg (20–96) versus 1, 000 mg (660-3, 300) consumed prehospitalization. Patients were easily trained and continued to use Syqe Inhaler for the duration of their hospitalization (5 [3–7] days). Pain intensity 30–60 minutes following inhalations was reported to be significantly lower than preinhalation 4 [1–5] versus 7 [2–9]). Participants ranked their satisfaction with Syqe Inhaler as 6 (5–7). Three participants reported mild cough, which resolved spontaneously. Significance of results: Cannabis inhalation by combustion is not feasible for hospitalized patients. The use of Syqe Inhaler during hospitalization yielded high levels of patients and staff satisfaction with no complications.